Sort
48,018 grants matching “immunotherapy”
Spore in Head and Neck Cancer
$500,001David Sidransky · Johns Hopkins University · P50 · FY2015 · DE
Abramson Cancer Center Support Grant
$500,000Robert H Vonderheide · University Of Pennsylvania · P30 · FY2023 · CA
Modulating T Cell Activation to Combat HIV Persistence
$500,000David Randolph Collins · Massachusetts General Hospital · DP2 · FY2024 · AI
NanoLuciferase-based AD/ADRD Microphysiological Systems Platform for High-throughput Screening
$500,000Wayne W Poon · Neucyte, Inc. · R41 · FY2024 · AG
Phase 2/3 Study of Toca 511-Toca FC vs SOC in Recurrent GBM-AA IND 14173 9Jul2015
$500,000Asha Das · Tocagen, Inc. · R01 · FY2017 · FD
Phase 2/3 Study of Toca 511-Toca FC vs SOC in Recurrent GBM-AA IND 14173 9Jul2015
$500,000Sophie Visonneau · Tocagen, Inc. · R01 · FY2019 · FD
Yale SPORE in Skin Cancer
$500,000Ruth Halaban · Yale University · P50 · FY2011 · CA
High Content Pathology
$500,000David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2018 · CA
Cancer Center Support Grant
$500,000D Gary Gilliland · Fred Hutchinson Cancer Research Center · P30 · FY2016 · CA
Targeting MCPyV to Overcome Immune Evasion in Merkel Cell Carcinoma
$500,000Paul Nghiem · University Of Washington · RC2 · FY2009 · CA
Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR)
$500,000Marcelo C. Pasquini · Medical College Of Wisconsin · U24 · FY2019 · CA
Arginase Production in Cancer: Evading Immune Response
$500,000Augusto C Ochoa · Lsu Health Sciences Center · R01 · FY2006 · CA
Validation of a novel treatment for glioblastoma using oncolytic Zika virus
$500,000Parvez Akhtar · Up Oncolytics, Inc. · R44 · FY2024 · NS
Targeting MCPyV to Overcome Immune Evasion in Merkel Cell Carcinoma
$500,000Paul Nghiem · University Of Washington · RC2 · FY2010 · CA
Definitive (GLP) Toxicity and Toxicology Studies for a Novel Small Molecule for Protection Against Cardiotoxicity in Triple Negative Breast Cancer
$500,000Cathy A Swindlehurst · Novomedix, Inc. · SB1 · FY2024 · HL
Cancer as a Complex Adaptive System
$500,000Robert A Gatenby · H. Lee Moffitt Cancer Ctr & Res Inst · U54 · FY2020 · CA
Modulating T Cell Activation to Combat HIV Persistence
$500,000David Randolph Collins · Massachusetts General Hospital · DP2 · FY2025 · AI
THE PARAPOXVIRUS ORF VIRUS (ORFV) HAS LONG BEEN RECOGNIZED FOR ITS UNIQUE IMMUNOMODULATORY EFFECTS ON VARIOUS ANIMAL SPECIES, AND ORFV PREPARATIONS ARE USED IN VETERINARY MEDICINE AS A PREVENTIVE AND THERAPEUTIC IMMUNOMODULATORY AGENT. HOWEVER, THE FUNCTIONS (GENES, PROTEINS, AND MECHANISMS OF ACTION) EVOLVED BY ORFV TO MODULATE HOST IMMUNE RESPONSES ARE POORLY UNDERSTOOD. WE HAVE IDENTIFIED NOVEL ORFV GENES WITH PUTATIVE VIRULENCE AND IMMUNOMODULATORY FUNCTIONS THAT LACK SIMILARITY TO OTHER VIRAL OR CELLULAR PROTEINS. WE HYPOTHESIZE THESE ORFV GENES ENCODE FOR NOVEL IMMUNOMODULATORY PROTEINS (IMPS).THE OBJECTIVES OF THIS STUDY ARE TO: 1) IDENTIFY NOVEL IMPS OF ORFV AND,DETERMINE THE MOLECULAR MECHANISM(S) BY WHICH ORFV IMPS INTERFERE WITH IMMUNE SIGNALING PATHWAYS AND2)DETERMINE FUNCTION(S) OF ORFV IMPS IN THE NATURAL HOST, INCLUDING ASSESSMENT OF ORFV IMP GENE-DELETED VIRUSES FOR VACCINE VECTOR POTENTIAL.WE ANTICIPATE THAT SUCCESSFUL COMPLETION OF THESE STUDIES WILL HAVE BROAD IMPACT ON IMMUNOVIROLOGY AND ON CURRENT UNDERSTANDING OF THE IMMUNOMODULATORY PROPERTIES OF ORFV. THE WORK WILL IDENTIFY AND CHARACTERIZE PROTEINS WITH NOVEL AND BROAD BASED IMMUNOMODULATORY ACTIVITIES SUITABLE FOR USE IN A VARIETY OF ANIMAL SPECIES POTENTIALLY OFFERING ADVANTAGES OVER EXISTING IMMUNOTHERAPIES AND POSITIVELY IMPACTING FORMULATION OF IMPROVED VACCINES, VACCINE VECTORS AND ADJUVANTS. IN ADDITION, AN IMPROVED UNDERSTANDING OF NOVEL VIRAL IMMUNOMODULATORY FUNCTIONS AND HOST RESPONSES IN THE SKIN MAY SUGGEST NEW AND IMPROVED STRATEGIES FOR CONTROLLING VIRAL AND OTHER DISEASES TARGETING SKIN AND MUCOSAL SURFACES.
$500,000University Of Illinois · · FY2020 · National Institute of Food and Agriculture
Treatment of Alzheimer's disease by clearing both tau and amyloid beta pathologies
$500,000Khalid Iqbal · Phanes Biotech, Inc. · R43 · FY2022 · AG
Phase 2/3 Study of Toca 511-Toca FC vs SOC in Recurrent GBM-AA IND 14173 9Jul2015
$500,000Sophie Visonneau · Tocagen, Inc. · R01 · FY2018 · FD
CAREER: Nanoparticle mRNA and DNA Immunoengineering of Macrophages for Solid Tumor Targeting
$500,000Michael J Mitchell · University Of Pennsylvania · · FY2022 · ENG
Miniaturized AD/ADRD Microphysiological Systems Platform for High-throughput Screening
$500,000Wayne W Poon · Neucyte, Inc. · R41 · FY2023 · AG
SPORE in Skin Cancer
$500,000John Munn Kirkwood · University Of Pittsburgh At Pittsburgh · P50 · FY2018 · CA
Coordinating Center for Canine Immunotherapy Trials and Correlative Studies
$499,999Nicola J Mason · University Of Pennsylvania · U24 · FY2020 · CA
SPORE in Brain Cancer
$499,999Duke University · P20 · FY2003 · CA